Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Receives $163.18 Consensus Target Price from Analysts

Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Get Free Report) has been assigned a consensus recommendation of "Moderate Buy" from the twenty-four analysts that are currently covering the firm, Marketbeat reports. Five equities research analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and one has issued a strong buy rating on the company. The average 1-year target price among analysts that have updated their coverage on the stock in the last year is $161.83.

SRPT has been the subject of several recent analyst reports. Scotiabank dropped their price objective on Sarepta Therapeutics from $105.00 to $80.00 and set a "sector perform" rating for the company in a research report on Thursday, March 20th. Morgan Stanley cut their target price on shares of Sarepta Therapeutics from $196.00 to $182.00 and set an "overweight" rating on the stock in a research report on Friday. HC Wainwright upgraded shares of Sarepta Therapeutics from a "sell" rating to a "neutral" rating and set a $75.00 price target for the company in a report on Wednesday, April 2nd. Deutsche Bank Aktiengesellschaft dropped their target price on Sarepta Therapeutics from $124.00 to $99.00 and set a "hold" rating for the company in a research report on Wednesday, March 19th. Finally, Cantor Fitzgerald reiterated an "overweight" rating and set a $163.00 target price on shares of Sarepta Therapeutics in a research report on Tuesday, March 18th.

Sarepta Therapeutics Price Performance

SRPT traded down $1.06 on Friday, hitting $53.57. 1,038,830 shares of the stock were exchanged, compared to its average volume of 1,391,284. The company has a debt-to-equity ratio of 0.93, a current ratio of 3.84 and a quick ratio of 3.03. Sarepta Therapeutics has a 12 month low of $48.01 and a 12 month high of $173.25. The firm has a market capitalization of $5.20 billion, a price-to-earnings ratio of 42.86 and a beta of 0.93. The business has a 50-day moving average of $86.82 and a two-hundred day moving average of $109.61.

Remove Ads

Insider Activity at Sarepta Therapeutics

In other Sarepta Therapeutics news, Director Claude Nicaise sold 2,491 shares of Sarepta Therapeutics stock in a transaction dated Wednesday, March 12th. The stock was sold at an average price of $99.64, for a total transaction of $248,203.24. Following the completion of the transaction, the director now owns 27,812 shares of the company's stock, valued at $2,771,187.68. The trade was a 8.22 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 7.70% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Sarepta Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in SRPT. Captrust Financial Advisors increased its position in shares of Sarepta Therapeutics by 15.2% in the third quarter. Captrust Financial Advisors now owns 3,871 shares of the biotechnology company's stock worth $483,000 after purchasing an additional 511 shares during the last quarter. Stifel Financial Corp boosted its stake in Sarepta Therapeutics by 99.3% in the third quarter. Stifel Financial Corp now owns 37,207 shares of the biotechnology company's stock worth $4,647,000 after buying an additional 18,537 shares in the last quarter. Kovitz Investment Group Partners LLC raised its stake in shares of Sarepta Therapeutics by 36.7% during the third quarter. Kovitz Investment Group Partners LLC now owns 2,814 shares of the biotechnology company's stock worth $322,000 after acquiring an additional 755 shares in the last quarter. M&T Bank Corp raised its position in Sarepta Therapeutics by 8.5% in the 3rd quarter. M&T Bank Corp now owns 4,462 shares of the biotechnology company's stock worth $558,000 after purchasing an additional 349 shares during the period. Finally, Geode Capital Management LLC increased its holdings in shares of Sarepta Therapeutics by 2.7% in the third quarter. Geode Capital Management LLC now owns 1,696,354 shares of the biotechnology company's stock worth $211,910,000 after buying an additional 44,306 shares during the period. Hedge funds and other institutional investors own 86.68% of the company's stock.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.